BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu X, Jiang DS, Wang J, Wang R, Chen T, Wang K, Cao S, Wei X. Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis. Drug Saf 2019;42:1025-33. [PMID: 31077091 DOI: 10.1007/s40264-019-00828-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Vouga Ribeiro N, Gouveia Melo R, Guerra NC, Nobre Â, Fernandes RM, Pedro LM, Costa J, Pinto FJ, Caldeira D. Fluoroquinolones Are Associated With Increased Risk of Aortic Aneurysm or Dissection: Systematic Review and Meta-analysis. Seminars in Thoracic and Cardiovascular Surgery 2020. [DOI: 10.1053/j.semtcvs.2020.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gatti M, Bianchin M, Raschi E, De Ponti F. Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. European Journal of Internal Medicine 2020;75:60-70. [DOI: 10.1016/j.ejim.2020.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
3 Abbott IJ, Roberts JA, Meletiadis J, Peleg AY. Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. Expert Rev Anti Infect Ther 2021;19:271-95. [PMID: 32820686 DOI: 10.1080/14787210.2020.1813567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Taher MK, Alami A, Gravel CA, Tsui D, Bjerre LM, Momoli F, Mattison D, Krewski D. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Expert Opin Drug Saf 2021;:1-8. [PMID: 34641748 DOI: 10.1080/14740338.2022.1993187] [Reference Citation Analysis]
5 Mounsey O, Schubert H, Findlay J, Morley K, Puddy EF, Gould VC, North P, Bowker KE, Williams OM, Williams PB, Barrett DC, Cogan TA, Turner KM, MacGowan AP, Reyher KK, Avison MB. Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region. J Antimicrob Chemother 2021:dkab310. [PMID: 34450630 DOI: 10.1093/jac/dkab310] [Reference Citation Analysis]
6 Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol 2019;75:1431-43. [DOI: 10.1007/s00228-019-02713-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Kuula LSM, Backman JT, Blom ML. Health service use and costs associated with fluoroquinolone-related tendon injuries. Pharmacol Res Perspect 2021;9:e00796. [PMID: 34086409 DOI: 10.1002/prp2.796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jun C, Fang B. Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection. BMC Cardiovasc Disord 2021;21:470. [PMID: 34583637 DOI: 10.1186/s12872-021-02258-1] [Reference Citation Analysis]
9 Suter C, Leemann H, Twerenbold R. "Ciprofloxacin-induced" bilateral quadriceps tendon rupture: A case report and conclusions of the recent literature. Trauma Case Rep 2021;32:100423. [PMID: 33665316 DOI: 10.1016/j.tcr.2021.100423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang M, Falconer M, Taylor L. A quantitative bias analysis of the confounding effects due to smoking on the association between fluoroquinolones and risk of aortic aneurysm. Pharmacoepidemiol Drug Saf 2020;29:958-61. [PMID: 32406104 DOI: 10.1002/pds.5019] [Reference Citation Analysis]
11 Nikol S, Mathias K, Olinic DM, Blinc A, Espinola-Klein C. Aneurysms and dissections - What is new in the literature of 2019/2020 - a European Society of Vascular Medicine annual review. Vasa 2020;49:1-36. [PMID: 32856993 DOI: 10.1024/0301-1526/a000865] [Reference Citation Analysis]
12 Dai XC, Yang XX, Ma L, Tang GM, Pan YY, Hu HL. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies. BMC Cardiovasc Disord 2020;20:49. [PMID: 32013928 DOI: 10.1186/s12872-020-01354-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Battaglia S, De Santis S, Rutigliano M, Sallustio F, Picerno A, Frassanito MA, Schaefer I, Vacca A, Moschetta A, Seibel P, Battaglia M, Villani G. Uridine and pyruvate protect T cells' proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study. Sci Rep 2021;11:12841. [PMID: 34145306 DOI: 10.1038/s41598-021-91559-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]